截至2025年7月11日收盘，三生国健（688336）报收于56.15元，较上周的55.38元上涨1.39%。本周，三 生国健7月11日盘中最高价报56.3元。7月9日盘中最低价报51.44元。三生国健当前最新总市值346.33亿 元，在生物制品板块市值排名8/50，在两市A股市值排名434/5149。 本周关注点 公司公告汇总：三生国健召开2025年第三次临时股东大会，审议通过《关于2025年度开展外汇套 期保值业务的议案》 公司公告汇总 三生国健药业（上海）股份有限公司2025年第三次临时股东大会于2025年7月11日在上海召开。会议由 公司董事会召集，董事长LOU JING先生主持，采用现场投票和网络投票相结合的方式表决，国浩律师 事务所苗晨和何佳玥律师见证。出席会议的股东和代理人共196人，持有表决权数量530,462,663股，占 公司表决权数量的86.0043%。会议审议通过了《关于2025年度开展外汇套期保值业务的议案》，表决 结果为：同意530,376,668股，占99.9837%；反对85,427股，占0.0161%；弃权568股，占0.0002%。律师 见证结论意见认为，本次股东大会的召集 ...

国浩律师(上海)事务所 法律意见书 国浩律师(上海)事务所 关于三生国健药业(上海)股份有限公司 2025 年第三次临时股东大会的 法律意见书 致:三生国健药业(上海)股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民 共和国证券法》(以下简称"《证券法》")和中国证券监督管理委员会《上市 公司股东会规则》（以下简称"《股东会规则》"）的规定,国浩律师(上海) 事务所接受三生国健药业(上海)股份有限公司(以下简称"公司")董事会的 聘请,指派律师现场见证了公司于 2025年7月11日 10:00 起在中国(上海)自由 贸易试验区李冰路 399 号公司会议室召开的公司 2025年第三次临时股东大会,并 依据有关法律、法规、规范性文件的规定以及《三生国健药业(上海)股份有限 公司章程》(以下简称"《公司童程》")的规定,对本次股东大会的召集、召 开程序、出席人员资格、大会表决程序等事宜进行了审查,现发表法律意见如下: 一、股东大会的召集、召开程序 公司董事会已于 2025 年 6 月 26 日在中国证监会指定信息披露网站上向公司 股东发出了召开 2025年第三次临时股东大会的会议通知 ...

证券代码：688336 证券简称：三生国健 公告编号：2025-037 三生国健药业（上海）股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 7 月 11 日 （二） 股东大会召开的地点：中国（上海）自由贸易试验区李冰 路 399 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的 优先股股东及其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 196 | | --- | --- | | 普通股股东人数 | 196 | | 2、出席会议的股东所持有的表决权数量 | 530,462,663 | | 普通股股东所持有表决权数量 | 530,462,663 | | 3、出席会议的股东所持有表决权数量占公司表决权 | 86.0043 | | 数量的比例（%） | | | --- | --- | | 普通股股东所持有表决权数量占公司表决权 ...

Core Viewpoint - Sanofi's stock price has increased by 3.73% this week, closing at 55.38 yuan, with a total market capitalization of 34.158 billion yuan, ranking 9th in the biopharmaceutical sector and 424th in the A-share market [1] Company Announcements - Sanofi will hold its third extraordinary general meeting of shareholders on July 11, 2025, to discuss a proposal for foreign exchange hedging business [1] - The meeting will be conducted using a combination of on-site and online voting, with online voting available during trading hours on July 11, 2025 [1] - The main agenda includes reviewing the proposal for conducting foreign exchange hedging business through collaboration with banks and financial institutions, aiming to mitigate foreign exchange market risks and enhance financial stability [1] - The total contract value for the proposed foreign exchange derivative trading business will not exceed 500 million USD or equivalent foreign currency, funded by the company's own resources [1] - The approval for this proposal has already been passed by the company's fifth board of directors at its ninth meeting [1]

Group 1 - The company is holding its third extraordinary general meeting of shareholders in July 2025 to ensure the orderly conduct of the meeting and protect the rights of shareholders [1][2] - Only authorized personnel, including shareholders, directors, supervisors, and invited guests, are allowed to enter the meeting venue [1][2] - Shareholders must arrive at the venue 30 minutes before the meeting to complete registration and present necessary identification documents [1][2] Group 2 - The meeting will announce the number of shareholders present and the total voting rights held before any latecomers can participate [2] - Shareholders have the right to speak, inquire, and vote during the meeting, but must adhere to the agenda and time limits for speaking [2][3] - The meeting will utilize both on-site and online voting methods, with results published in a company announcement [3][4] Group 3 - The company plans to conduct foreign exchange hedging activities to mitigate risks associated with currency fluctuations, with a total contract value not exceeding 500 million USD or equivalent foreign currency [4][5] - The funding for these hedging activities will come from the company's own funds and will not involve raised capital [5] - The hedging activities are intended to enhance financial stability and efficiency, following principles of legality, prudence, safety, and effectiveness [5]

证券代码：688336 证券简称：三生国健 三生国健药业（上海）股份有限公司 2025 年第三次临时股东大会会议资料 1 目录 | 2025 | 年第三次临时股东大会会议须知 | | 3 | | --- | --- | --- | --- | | 2025 | 年第三次临时股东大会会议议程 | | 6 | | 2025 | 年第三次临时股东大会会议议案 | | 8 | | 议案 | 1、《关于 2025 | 年度开展外汇套期保值业务的议案》 | 8 | 2 三生国健药业（上海）股份有限公司 2025 年第三次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事 效率，保证大会的顺利进行，根据《中华人民共和国公司法》《中华 人民共和国证券法》《上市公司股东会规则》以及《三生国健药业（上 海）股份有限公司章程》（以下简称"《公司章程》"）、《三生国 健药业（上海）股份有限公司股东大会议事规则》等相关规定，特制 定 2025 年第三次临时股东大会会议须知。 二〇二五年七月 六、股东及股东代理人要求发言时，不得打断会议报告人的报告 或其他股东及股东代理人的发言，在股东大会进行表决时，股东及股 ...

三生国健 20250627 摘要 2024 年公司研发投入达 5.4 亿元，因产品临床推进加速，现金储备 33 亿元，资金稳健。聚焦自免领域，管线数量增至 22 个，重点布局高发 病率及临床解决方案不足的自免疾病，目标未来五年内每年至少一到两 个产品提交 NDA 申报。 2025 年是数据读出大年，8 个产品将进入下一阶段，包括 2 个产品推 进到二期临床，5 个产品的相关适应症推进到三期临床，以及 1 个产品 推进到 NDA 状态，保障每年有一到两个产品提交 NDA 申报。 白介素 17A 产品（608）银屑病适应症已提交 NDA，强直性脊柱炎和 放射性阴性脊柱炎适应症将于 2025 年推进到三期临床。有效性方面， 核心指标改善超 90%，且持续缓解率高；安全性方面，Ada 发生率低于 2%。 伊赛普面临招标和指标压力，预计今年三款已上市产品仍将实现个位数 增长。白介素-17 产品预计 2025 年获批，计划 2024 年 Q4 组建销售团 队，竞争优势在于疗效、低不良反应率和 Q8W 给药方案。 Q&A 2024 年公司整体业绩表现如何，主要增长来源和利润构成是怎样的？ 2024 年公司营业收入达到 11 ...

Core Viewpoint - The company, Sangfor Technologies, is actively engaging in foreign exchange hedging activities to mitigate market risks and enhance financial stability while also adjusting its stock incentive plan to align with its strategic goals [3][5][8]. Company Announcements - Sangfor Technologies' board meetings on June 25, 2025, approved several key resolutions, including the convening of a temporary shareholders' meeting on July 11, 2025, to discuss foreign exchange hedging [2][5]. - The company plans to conduct foreign exchange hedging activities with a transaction amount not exceeding $5 billion or equivalent foreign currency, using its own funds [3][5]. - The company has adjusted the grant price for its 2024 restricted stock incentive plan from 11.95 yuan/share to 11.83 yuan/share, with the grant date set for June 25, 2025 [4][8]. Stock Incentive Plan - The company will grant 1.157 million shares of restricted stock to 43 incentive targets at a price of 11.83 yuan/share, which represents 0.19% of the total share capital [7][9]. - The incentive plan includes a two-phase vesting schedule, with shares vesting after 12 and 24 months, and a six-month lock-up period post-vesting [7][9]. - The total estimated expense for the stock incentive plan is approximately 41.18 million yuan, to be amortized from 2025 to 2027 [7].

Core Viewpoint - The legal opinion letter from Grandall Law Firm confirms that the stock incentive plan of Sangfor Technologies (Shanghai) Co., Ltd. has obtained necessary approvals and complies with relevant regulations, including adjustments to the grant price and the allocation of reserved stock options [1][14]. Group 1: Implementation of the Incentive Plan - The company has approved the 2024 Restricted Stock Incentive Plan and its related proposals, with independent directors recusing themselves during the voting process [5]. - The supervisory board has verified the eligibility of the proposed incentive recipients and confirmed their compliance with legal and regulatory requirements [5][6]. Group 2: Grant Price Adjustments - The initial grant price was adjusted from 12.00 RMB to 11.95 RMB per share due to a cash dividend distribution of 0.05 RMB per share [7][10]. - The reserved stock grant price was further adjusted to 11.83 RMB per share, following a second dividend distribution of 0.09 RMB per share [9][10]. Group 3: Grant Conditions and Recipients - The incentive plan's recipients meet the conditions set forth in the 2024 Restricted Stock Incentive Plan, and the granting of restricted stocks is deemed valid [12][14]. - A total of 115.70 million shares will be granted to 43 recipients at the adjusted price of 11.83 RMB per share [13][14]. Group 4: Disclosure Obligations - The company is required to fulfill its information disclosure obligations in accordance with relevant laws and regulations, ensuring transparency regarding the incentive plan's progress [14].

三生国健药业(上海)股份有限公司监事会 关于公司 2024 年限制性股票激励计划预留授予激励对象 名单的核查意见(截止授予日) 三生国健药业(上海)股份有限公司(以下简称"公司")监事会依据《中 华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》 (以下简称"《证券法》")、《上市公司股权激励管理办法》(以下简称"《管 理办法》"）、《上海证券交易所科创板股票上市规则》(以下简称"《上市规 则》"）、《科创板上市公司自律监管指南第 4 号 -- 股权激励信息披露》等相 关法律、法规及规范性文件和《三生国健药业(上海)股份有限公司章程》（以 下简称"《公司章程》")的有关规定,对公司 2024年限制性股票激励计划(以 下简称"本激励计划"）预留授予激励对象进行了核查,发表核查意见如下; 1、本激励计划预留授予激励对象均不存在《管理办法》第八条规定的不得 成为激励对象的情形; (1) 最近 12个月内被证券交易所认定为不适当人选; (2) 最近 12个月内被中国证监会及其派出机构认定为不适当人选; (3) 最近 12个月内因重大违法违规行为被中国证监会及其派出机构行政 处罚或者采取市场禁入措 ...